Objective: To investigate proteins associated with neuronal damage in plasma neuronderived exosomes (NDE) of HIV-infected study participants as a liquid biomarker for cognitive impairment.
Introduction
In the setting of antiretroviral therapy (ART), viral loads for most HIV-infected individuals remain undetectable; however, for some individuals on therapy, spikes in viral load in the periphery, and chronic inflammation remain as well as a spectrum of neurological deficits termed HIVassociated neurocognitive disorder (HAND). HAND develops in a portion of patients ranging from 20 to 69% and for the most part, is more frequent in study participants who are not virally suppressed [1] . Biomarkers to assess neurological involvement should be objective, inexpensive, easily accessible, noninvasive tools to monitor the course of infection, and identify those at risk for neurological damage. Although cerebrospinal fluid (CSF) is thought to be closest to the neuropathology, it is an invasive procedure and like plasma will have a complex protein profile comprised of different cell types. With increased aging of HIV-infected study participants, biomarkers also need to separate normal cognitive changes because of age from that associated with HIV infection. Exosomes are 30-150 nm microvesicles formed in late endosomes and collected as multivesicular bodies prior to fusion with the plasma membrane [2] [3] [4] . They are shed from various cells under normal as well as pathological conditions into the surrounding milieu including plasma, urine, saliva, and inflammatory tissues. The cellular cargo packaged into exosomes can be significantly altered depending on the physiological state of the parent cell including immune activation [4] . Most cells in the central nervous system (CNS), including neurons, astrocytes, oligodendrocytes, and microglia shed exosomes (Review [5] ). These extracellular vesicles are secreted by neural cells under normal and pathological conditions and have been isolated from the CSF [6] , adult human brain [7] , and recently plasma [8] [9] [10] [11] . Exosomes can reflect the host cell proteins and nucleic acids at the time of secretion and can be taken up by recipient cells, thereby, altering their function and setting off a cascade of events that alter homeostasis. Exosomes can diffuse across the blood-brain barrier into the periphery and be captured by antibodies directed against the cell surface proteins embedded in the vesicle membrane. This strategy has been used to isolate neuron-derived exosomes (NDE) [10] .
In this pilot study, our goal was to begin to identify a plasma biomarker profile to determine the functional state of neurons in HIV infection. We report that NDE from cognitively impaired study participants, regardless of HIV infection, have an increase in proteins associated with neuronal damage. We also show that there are decreases in these NDE proteins with age in HIV-infected study participants compared with normal controls.
Materials and methods
Study participants characteristics and plasma collection Individuals were recruited from the San Francisco Veterans Affairs Medical Center (SFVAMC). All participants provided written consent approved by the University of California, San Francisco Committee on Human Research. HIV-infected study participants were on stable ART, whereas controls were healthy individuals receiving care at the SFVAMC. Exclusion criteria included psychoactive drug use, alcoholism, clinical depression or psychiatric disease, seizure disorder, or history of head injury. Whole blood was collected using BD Vacutainer Heparin tubes (BD, Franklin Lakes, New Jersey, USA) and centrifuged at 300 g for 10 min. Plasma was collected, aliquoted and frozen at À808C.
Neuropsychological evaluation
All study participants were tested for neuropsychological performance within 2-3 days of the blood draw. Neuropsychological testing was performed by the same trained psychologist (L.A.). All study participants underwent seven domains of neuropsychological testing as previously described [12] . The seven domains tested included: attention working memory, information processing speed, executive function, fine motor skills, verbal fluency and verbal learning, and memory. Neuropsychological evaluation results were demographically corrected per educational level, sex, and age. Raw individual test scores were converted to standard T scores. Two or more domains below 1.5 SD from the norm was determined as neuropsychologically impaired (NPI), otherwise, neuropsychologically normal (NPN).
Isolation of exosomes About 1 ml frozen plasma was thawed, centrifuged at 1000 g for 15 min at 48C. Exosome isolation followed Goetzl et al. protocol [13] . Briefly, 0.75 ml plasma was incubated with 0.3 ml thromboplastin-D (ThermoFisher Scientific, Inc., Waltham, Massachusetts, USA) for 1 h at room temperature. After addition of 0.45 ml PBS with 3Â protease inhibitors (Sigma-Aldrich Corp. St. Louis, Missouri, USA) and phosphatase inhibitors (Thermo-Fisher Scientific, Inc.), samples were mixed and centrifuged at 3000 g for 20 min. The supernatants were mixed with 378 ml of ExoQuick (System Biosciences, Inc., Palo Alto, California, USA) and incubated for 1 h at 48C. Exosomes were collected and resuspended in water with protease and phosphatase inhibitors. These were total exosomes. The exosome suspension (700 ml) was incubated with 4 mg mouse antihuman L1 cell adhesion molecule (L1CAM)-biotinylated antibody (CD171, clone 5G3; eBiosciences, San Diego, California, USA) and bound to 20 ml Streptavidin-plus ultralink resin (Thermo-Fisher Scientific, Inc.) for 1 h at 48C. Following centrifugation at 400 g for 10 min at 48C, each pellet was resuspended with 200 ml 50 mmol/l glycine-HCl (pH 3.0). Supernatants were neutralized with 20 ml of 1 mol/l Tris-HCl (pH 8.0). These were NDE. Each 100 ml NDE were lysed with 365 ml mammalian protein extraction reagent (Thermo-Fisher Scientific, Inc.) with 25 ml of 3% BSA and protease and phosphatase inhibitors. The samples were mixed and subjected to two cycles of free thaw and stored at À208C.
NanoSight analysis
Exosome size and count were determined by a nanoparticle characterization system, NanoSight LM10 instrument (Malvern Instruments, Malvern, UK) with a 405 nm laser-equipped sample chamber, as described previously [14] . The samples were diluted in PBS to 10 8 -10 9 particles/ml. Camera shutter, gain and software detection threshold were manually adjusted for optimal detection. Each sample was analyzed three times. Each analysis consisted of three recordings of 40 s each. As the distributions of the sizes were highly skewed, the modes were reported for particle size. The mean of the triplicate recordings was reported for size and concentration.
ELISA
The samples were thawed, vortexed, and centrifuged before ELISA analysis. Neuronal markers were quantified using ELISA kits for human neurofilament light protein (NF-L; MyBioSource, San Diego, California, USA) and synaptophysin (SYP; American Research ProductsCusabio, Waltham, Maine, USA). Tetraspanin exosome markers were tested using human CD81 (American Research Products Cusabio) and CD63 (MyBioSource). Mediators of neuronal dysfunction included highmobility group protein B1 (HMGB1, LifeSpanBioSciences, Inc., Seattle, Washington, USA) and human amyloid b (Ab) 42 Ultrasensitive ELISA Kit (ThermoFisher Scientific, Inc.).
Statistical analysis
The differences of the means between groups were tested using two-tail unpaired Student's t-test assuming unequal variances. Log 10 transformation was performed before tests to obtain Gaussian distribution. When concentrations of ELISA data contained zero values, zeros were replaced with half of the otherwise minimum data point to perform log transformation. Contingency tables were analyzed with x 2 test or Fisher's exact test where appropriate. When comparing multiple groups, the analysis of variance (ANOVA) was used. Significance was determined by P < 0.05. P values for multiple tests were corrected using Benjamini and Hochberg's adjustment [15] . All statistical analyses were performed in R statistical software version 3.3.2 (R Foundation, Vienna, Austria).
Results

Study population
The characteristics and clinical and laboratory data for the participants are summarized in Table 1 . Study participants were all men except for one women, representing the demography of patients cared for at the SFVAMC. The ages ranged from 35 to 67 years [interquartile range (IQR) 50.5-60]. There was no difference in age among the groups. There were 12 HIV-negative controls, including nine NPN and three impaired. All controls were recruited without prior knowledge of their neuropsychological status. Three controls, after testing and in spite of exclusion criteria, were found to have non-HIV-related mild impairment. The 23 HIV-infected study participants included 11 undetectable HIV viral load (<40 copies/ml) and 12 with plasma HIV viral load at the time of blood draw. The number of study participants in each group was not significantly different. There was no difference in viral load between the NPI and NPN HIV-infected groups. The study participants were primarily Caucasian in all groups. Plasma CD4 þ cell counts were lower in the HIV NPI group compared with controls; however, there was no significant difference in CD4 þ cell counts between NPN and NPI HIV-infected individuals.
Exosomes are decreased in HIV-infected and cognitively impaired study participants Exosomes were counted using the NanoSight system as previously described [14] . The size of total exosomes (108 AE 30 nm) and NDE (106 AE 28 nm) were similar (P ¼ 0.73). The size of NDE were similar between Blood neuron-derived exosomes as biomarkers in HIV Sun et al. F11 impaired (103 AE 29 nm) and nonimpaired (108 AE 28 nm, P ¼ 0.65) study participants. The number of total exosomes was fewer in HIV-infected study participants compared with controls ( Fig. 1a top-left panel, 2.2 AE 0.7 vs. 2.6 AE 0.3, log 10 transformed, Â 10 9 particles/ml, P ¼ 0.027). The number of NDE was fewer in neurocognitively impaired study participants compared with nonimpaired ( Fig. 1a bottom-right panel, 0.6 AE 0.8 vs. 1.2 AE 0.5, log 10 transformed, Â 10 9 particles/ml, P ¼ 0.034), whereas the number of total exosomes was similar between NPN and NPI study participants (P ¼ 0.57).
Exosomal proteins are differentially expressed in HIV infection
To further characterize exosomes, tetraspanins CD63 and CD81 were evaluated using ELISA. The levels of CD63 and CD81 were enriched in both total exosomes and NDE (Fig. 1b) . Plasma contained measurable levels of CD63 (range 317-896 pg/ml) and CD81 (range 87-165 pg/ml). Total exosomes isolated from plasma were enriched for CD63 and CD81. Although the total amount of CD63 was lower in the NDE, the number of NDE was only 5.2% of total exosomes; this indicates CD63 was actually highly enriched in NDE. CD81 was also highly enriched in NDE. We found that the level of CD63 from NDE was increased in HIV individuals (P ¼ 0.045), whereas CD81 was decreased (P ¼ 0.048) (Fig. 1b) . As exosome counts were not changed between controls and HIV study participants (Fig. 1a, bottomleft), we chose exosome counts as the normalization tool. To confirm the exosomes were derived from neurons, we evaluated neuronal markers using ELISA. The levels of the neuronal markers, NF-L and SYP were enriched significantly in NDE by 86 and 951-fold, respectively, compared with total exosomes (Fig. 1c) .
Markers of neuronal damage increased in neuron-derived exosomes from impaired study participants To investigate the effects of neurocognitive impairment, we chose four protein targets to assess neuronal damage, HMGB1, NF-L, Ab, and SYP. There were no significant differences in protein levels of NDE between HIVinfected and uninfected study participants (data not shown). However, NDE from NPI study participants showed significant increases in HMGB1 (5.1-fold change, P ¼ 0.023), NF-L (3.8-fold change, P ¼ 0.041), and Ab . Plasma data included two controls and three HIV-infected study participants for CD63 and two controls, five HIV-infected study participants for CD81 analyses. Because no difference was found between plasma control and HIV levels for either CD63 or CD81, the two groups were combined. Concentrations of CD63 and CD81 were log10 transformed. The BoxWhisker plot indicates the 25th, 50th, and 75th percentile within the Box-Whiskers extending from the boxes indicate extreme values within 1.5 interquartile range from the 25th to 75th percentile respectively and the circles indicate outliers. (c) The source of NDE was further confirmed with neuronal markers. NF-L and SYP were both enriched in NDE compared to total exosomes. Concentrations of NF-L and SYP were normalized to exosome counts and log 10 transformed. Horizontal bars indicate group means. Two-tailed Student's t-test with Benjamini and Hochberg multiple test correction was used. Ã P < 0.05, ÃÃ P < 0.01, ÃÃÃ P < 0.001. NDE, neuron-derived exosomes; NF-L, neurofilament light; NPN, neuropsychologically normal; SYP, synaptophysin.
(6.2-fold change, P ¼ 0.048) compared with NPN study participants (Fig. 2a) . SYP showed no difference (P ¼ 0.11) between these two groups (Fig. 2a) . Interestingly, tetraspanin CD63 increased 5-fold (P ¼ 0.023) and CD81 had a trending increase of 2.3-fold (P ¼ 0.069) (Fig. 2b) . The levels of all these analytes showed no difference between NPI and NPN in total exosomes. This strongly suggests that plasma total exosomes may not adequately reflect neuronal damage. In addition, the NPI group was a mixture of HIV-infection status and included not only HIV controlled study participants (N ¼ 5), but also study participants with a viral load (N ¼ 6) and HIVnegative study participants (N ¼ 3).
Aging changes exosomal proteins in HIV-infected study participants
The age range of our study participants was 35-67 years and would not be considered in the older age range associated with Alzheimer's disease. HIV-infected study participants showed a positive correlation between age and NDE counts (R ¼ 0.46, P ¼ 0.028), whereas control study participants showed no correlation (Fig. 3a) . The controls in this study were older although not significantly (57.5 vs. 53.3 years in HIV, P ¼ 0.079) and had a relative narrower age range (51-65 years, IQR: 54-60.5) compared with the HIV-infected study participants (35-67 years, IQR:46-60). To investigate the effects of age on each of the markers, we performed linear regression analysis. There were no correlations with the target proteins in NDE and age in the controls although the limited age distribution may affect this conclusion. HMGB1 levels in NDE showed a negative correlation with age in HIV-infected patients (R ¼ À0.51, P ¼ 0.014; Fig. 3b) . A trending negative correlation was observed between age and NF-L (R ¼ À0.41, P ¼ 0.051) and Ab (R ¼ À0.39, P ¼ 0.067) in NDE. Furthermore, the tetraspanins CD63 and CD81 also showed a trending decrease with age.
Discussion
The small pilot study showed that NDE are influenced by both HIV infection and neurocognitive impairment. The study was initiated with the expectation that HIV infection would alter neuronal function and be different from HIV-negative controls. What was surprising was that the impaired study participants tended to cluster together and HIV infection appeared to influence the numbers of total exosomes and NDE. Our findings showed that total exosomes isolated from plasma did not show differences in several distress proteins between HIVinfected and control study participants (data not shown). When we grouped the study participants into cognitive impairment vs. normal cognition, there still was no difference in the levels of targeted proteins in total exosomes. However, we began to see these elevated stress Blood neuron-derived exosomes as biomarkers in HIV Sun et al. proteins in isolated NDE from impaired study participants compared with normal individuals. This implies that NDE may be a better reflection of cognitive impairment than plasma exosomes and more accurate biomarker of neuronal damage.
We utilized a two-step purification technique to isolate exosomes secreted from neurons. After total exosome isolation from plasma, NDE were captured using the neuron-specific L1CAM mAb. This procedure has been successfully used to predict Alzheimer's disease [10, 11, 16, 17] . We found that total exosome counts were lower in HIV infection but the same in NDE counts. Total plasma exosomes can originate from all blood cell types [18] but tend to be enriched from platelets, dendritic cells, and monocytes [19] . Fewer total exosomes may reflect a loss in one of these cells types. On the other hand, NDE from NPI study participants were significantly fewer (52%) than unimpaired study participants. We speculate that neurons in neurocognitively impaired individuals may secrete less exosomes because they are stressed or it may be because of loss of neurons.
To further characterize the NDE, we quantified several tetraspanins. The role of tetraspanins has evolved from markers of transmembrane domains used to identify exosomes to functional regulators of migration and signaling (Review [20] ). We showed that NDE from HIV-infected individuals were increased in CD63 and decreased in CD81; however, both tetraspanins were increased in cognitively impaired study participants compared with cognitively normal study participants.
Although there is scant data as to the role of these tetraspanins in HIV infection, reports show that HIV acquires CD63 upon budding from cells [21] . Similarly, HIV can be internalized in astrocyte CD81 vesicles that can transinfect other cells without de novo virus production [22] . Although the functions of these tetraspanins in neurons are unclear, these studies suggest that CD63 and CD81 may participate in HIV infection. /ml plasma. (b) HMGB1 decreased significantly with age in NDE from study participants with HIV infection; NF-L, Ab, and tetraspanins CD63 and CD81 were trending decrease with age in HIV infection. No effect was seen in NDE isolated from controls. Exosome protein levels were log 10 transformed. Nonparametric Spearman correlation was used. Ab, amyloid b; HMGB1, high-mobility group box 1; NF-L, neurofilament light; NDE, neuron-derived exosomes.
We chose several target proteins associated with HIV and stress to analyze neuronal injury. HMGB1 is a dangerassociated molecular patterns molecule and an alarmin, which is released from necrotic cells and serves as a 'danger signal' to the immune system. It is a nuclear DNA-binding protein expressed in all cell types, including neurons and glial cells [23] . Passively released HMGB1 by necrotic or injured cells results in inflammation initiation, whereas actively secreted HMGB1 by immune cells, once released into extracellular space, can promote neuroinflammation [23] [24] [25] . HMGB1 is a proinflammatory mediator and directly involved in HIV replication and reactivation [26] . HMGB1 binds to receptors toll-like receptor (TLR)-2, TLR-4, and the receptor for advanced glycation endproducts and propagates inflammation in a positive feedback manner in traumatic brain injury (TBI) [27] [28] [29] . Also, HMGB1 was elevated in CSF after TBI [29] . Investigations of acute death from TBI found that HMGB1 was partly lost in neurons and increased in the cytoplasm of infiltrating phagocytic microglia [27] . HMGB1 was recently reported to be elevated in the CSF from HIV-infected study participants on stable ART, strongly suggesting persistent inflammation in the CNS and potentially a biomarker for early cognitive impairment [30] . HMGB1 was increased in the brains of study participants with Alzheimer's disease, colocalized with Ab in senile plaques and thought to promote neuronal death and synaptic malfunction [31] . Collectively, HMGB1 is associated with neuronal damage and neurocognitive impairment. It is consistent with our findings that HMGB1 increased in NDE of NPI study participants. We posit that chronically injured neurons release exosomes containing higher levels of HMGB1. Neurons may utilize this route to remove cytotoxic HMGB1 from the cytoplasm or passively signal neuronal cell death. The NDE-containing HMGB1 may also behave as a vehicle disseminating HMGB1 in the brain and activating astrocytes and microglia with further damage to neurons. NF-L is an axonal degeneration marker. CSF NF-L was the most sensitive neuronal marker from several targets tested, including total and phosphorylated t, soluble amyloid precursor proteins, and Ab fragments in a study evaluating eight different degrees of HIV infection [32] . CSF NF-L was over 10-fold higher in only HIVassociated dementia [32] . In another study, CSF NF-L levels were recognized as a sensitive neuronal injury marker in milder neurocognitive impairment in HIV infection [33] [34] [35] . CSF NF-L increased in HIV and correlated with magnetic resonance spectroscopy markers of neuronal injury [33] . Our results showed that NDE from impaired study participants had increased NF-L, which indicates neuronal damage.
Amyloid b has been strongly associated with Alzheimer disease. Amyloid b can trigger neuroinflammation, oxidative stress, and cell signaling (Review [36] ). We along with others have reported that Ab is increased in the brains of HIV-infected study participants [37] [38] [39] and might contribute to an Alzheimer-like pathology or the development of HAND. However, to our knowledge there are no reports of an increase in Alzheimer's disease among HIV-infected study participants. Therefore, we suggest that neuronal accumulation of Ab may impair memory by direct toxicity or disruption in synaptic plasticity or the dissemination of Ab in NDE. In HIVrelated neurodegeneration, the role of Ab 42 in CSF is not clear and the reports are less consistent [40] [41] [42] . Amyloid b 42 increased in CSF from HIV individuals with blood-brain barrier disruption [43] . A recent report showed increased exosome secretion and increased exosomal Ab cargo in HIV-infected brain endothelial cells [44] . NDE were initially studied to identify Alzheimer's disease-related proteins Ab 42 and forms of t that distinguished cognitively normal controls from patients with frontal temporal dementia or Alzheimer's disease [8] . In a recent study, NDE showed increased Ab in mild cognitive impairment and pre-Alzheimer's disease patients [8] ; mild cognitive impairment converting to Alzheimer's disease had the highest Ab level that decreased when a diagnosis of Alzheimer's disease was made [45] . In the present study, we showed that Ab increased in NDE from NPI study participants and this difference was not associated with HIV infection but rather with neurocognitive impairment.
Tetraspanins CD63 and CD81 are involved with g-secretase activity and neurocognitive dysfunction [46] . Knockout of CD81 or use of CD81-deficient mice strongly decreased the activity of g-secretase and subsequently decreased Ab production [46] . CD63 was also found associated with the g-secretase complex and presenilin interacting proteins [47, 48] . The increased levels of CD63 and CD81 in NDE from NPI study participants were concomitant with increased Ab levels.
When looking at exosomes as biomarkers of disease, one must consider normal aging and how this will affect the composition of exosomes. It will be important to investigate concentration and content changes in exosomes in age-related pathologies. A recent report showed that the concentration of extracellular vesicles from normal study participants decreased with aging [49] . Our data from controls showed no correlation; however, this discrepancy may be because of the age of our controls, which spanned a relatively narrow range of middle age. In addition, the source of the exosomes would greatly influence concentration and content. With HIV infection, although the number of study participants observed was small, there appeared to be an increase in the concentration of NDE with age that may be specific to HIV infection. An increase in neuronal exosome secretion in vitro was reported to follow extensive synaptic activation [50] . Another report showed that premature cellular senescence caused an increase in secretion of exosomes [51] . Despite the increased concentration, we observed a significant decrease in HMGB1 protein and trending decrease in NF-L and Ab with age. A recent report on aging found that extracellular vesicles content might change with normal aging [49] . Although the function of HMGB1 in brain is little understood, it appears that it can regulate DNA repair mechanisms. In mouse brain, HMGB1 gradually decreased in neurons during aging, which was reported to be from an accumulation of DNA double-strand breaks [52] . In contrast, HMGB1 was increased in astrocytes with aging, with no demonstrable accumulation of DNA doublestrand breaks. It is interesting to speculate that a decrease in neuronal HMGB1 with aging may be associated with the accumulation of DNA damage guiding neuronal dysfunction.
The goal of this study was to begin to characterize blood NDE that might identify neurocognitive changes associated with HIV infection. Although the study participant numbers are small, we are beginning to see some changes both in HIV-infected and normal study participants and more importantly, between cognitively impaired and unimpaired study participants. Our results did not show a direct correlation between HIV status and impairment nor an increase in stress markers in NDE only from HIV-infected study participants. This is encouraging as cognitive impairment occurs in only some individuals; not all individuals with HIV infection are impaired. Interestingly, in this study, even a few study participants with breakthrough viral load were not impaired showing that viral load did not always correlate with cognitive impairment. This study involves a small number of study participants and target proteins and needs further investigation. Factors that drive HIVassociated neurological involvement are probably not specific to HIV infection alone but rather a general neurodegenerative process. This study demonstrated the utility of isolating and characterizing NDE in HIV infection as a reflection of neuronal function in living study participants. By studying NDE, new neuronal stress proteins or profile can be identified to give an emerging liquid biopsy that can be followed throughout infection and with new therapies.
